Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04277637 · ClinicalTrials.gov registry record · Phase 1
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
A Phase 1 study of Mature B-cell Malignancies, sponsored by BeiGene.
- Active
- Registry status
- Phase 1
- Development phase
- 437
- Enrollment target
- 20
- Study locations
NCT04277637: Active Phase 1 study of Mature B-cell Malignancies, sponsored by BeiGene.
NCT04277637 is a Phase 1 study of Mature B-cell Malignancies that is active but no longer recruiting, run by BeiGene. The registered enrollment target is 437 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (628% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04277637, a Phase 1 study of Mature B-cell Malignancies, is active but no longer recruiting, sponsored by BeiGene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 437 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Obinutuzumab
- DRUG Sonrotoclax
Study Locations (20)
New York
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center Mskcc - New York
New South Wales
- Concord Repatriation General Hospital - Concord
- Orange Health Service (Central West Cancer Care Centre) - Orange
Queensland
- Pindara Private Hospital - Benowa
- John Flynn Private Hospital - Tugun
South Australia
- Royal Adelaide Hospital - Adelaide
- Flinders Medical Centre - Bedford PK
California
- UCLA Hematologyoncology - Los Angeles
Illinois
- Northwestern University - Chicago
Kansas
- University of Kansas Medical Center Research Institute - Kansas City
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 437 participants |
| Start Date | 2020-03-24 |
| Est. Completion | 2027-08-30 |
| Phase | Phase 1 |
What the registry record for NCT04277637 still lists
NCT04277637 is an interventional study that assigns participants to a tested intervention. The registered 437 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (628% higher).
The record links to 1 condition, with Mature B-cell Malignancies appearing as the primary indexed condition, and to 3 interventions - of which Zanubrutinib is the first listed.
NCT04277637 names 20 study sites across 16 states, led by New York, New South Wales, Queensland.
Frequently Asked Questions
What is clinical trial NCT04277637 about?
NCT04277637 is a clinical study titled "Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies". The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination w...
What is the current status of trial NCT04277637?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 437 participants. The study started on 2020-03-24. Estimated completion is 2027-08-30.
What conditions does trial NCT04277637 study?
This clinical trial studies the following conditions: Mature B-cell Malignancies.
What interventions are being tested in trial NCT04277637?
The interventions under investigation include: Zanubrutinib (DRUG), Obinutuzumab (DRUG), Sonrotoclax (DRUG).
Who is sponsoring clinical trial NCT04277637?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04277637 being conducted?
This trial has 20 study locations across California, Illinois, Kansas, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mature B-cell Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04277637's enrollment target sits among peer trials
437 62nd of 2000 higher than 1,939 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05711446 · 438 participants · NA
Double Voiding and Post-transplant UTI
- NCT02622542 · 436 participants · NA
ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy
- NCT05918211 · 436 participants · Phase 3
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
- NCT06966479 · 436 participants · Phase 2
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI